Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).
Emerging research on the prevention and treatment of Clostridioides difficile infection (CDI) shows exciting potential for improved patient care over the next 5 years, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Is there any emerging research you find noteworthy in the management of CDI and any gaps in knowledge that warrant further investigation, such as pediatric care?
I think a lot of these [therapies] have not been studied in pediatrics, and certainly, that is a huge gap. I think what's also exciting in this space is that Rebyota [fecal microbiota, live-jslm] is not the only LBT [live biotherapeutic] that has been being explored.
We know that Seres Therapeutics has their own capsule formulation that is being considered by the FDA right now for approval. There's also Vedanta Biosciences and Finch Therapeutics, which also have products in phase 3 clinical trials right now. I think this is an area that is rapidly expanding. So, overall, great for the field and great for patients, because there's going to be a lot of options to prevent recurrent C diff down the line.
Overall, I would just say C diff, again, continues to be a major health care issue. Again, it's still at epidemic levels. And so, I'm really thrilled to see that we're finally moving the needle forward with microbiome-based therapies. Antibiotics are not going anywhere; we're still using antibiotics to treat these [patients]. But I think this is a huge step forward, not only for the science in this field, but also for patient care. I think over the next 5 years, we're going to see major advancements, and I certainly hope at some point C diff is an issue that patients don't have to deal with anymore and we ultimately have a cure.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More